Biotech startup Immuneel Therapeutics secured over ₹100 crore in a Series B round with participation from Singularity AMC and Rainmatter.
The funds will aggressively accelerate the commercialization of Qartemi, India's first approved homegrown CAR-T therapy for blood cancers.
By manufacturing locally, the company offers complex genetic therapies at a fraction of the standard Western cost.
The fresh capital will also underwrite the expansion of localized GMP manufacturing and international market entry across the Asia-Pacific and Middle East.
Read the full story on StartupFox